Bristol-Myers Squibb Company
Combination of anti-LAG-3 antibodies and anti-PD-1 antibodies to treat tumors
Last updated:
Abstract:
Provided are methods for clinical treatment of tumors (e.g., advanced solid tumors) using an anti-LAG-3 antibody in combination with an anti-PD-1 antibody.
Status:
Grant
Type:
Utility
Filling date:
11 Sep 2020
Issue date:
15 Mar 2022